Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 10, 2013
According to Laboratory LESCUYER®, this is the first time a patented dietary supplement has ever received a favorable opinion for a health claim in Europe. LIMICOL® is also the first dietary supplement to benefit from the protection of proprietary data relating to a disease risk claim.
Laboratory LESCUYER® is waiting on final approval from the European Commission to state this recognition on its patented formula.
EFSA represents the highest European authority for food safety and consists of a panel of experts in nutrition. EFSA scientifically recognized the health benefits of LIMICOL® and its claims to reduce blood LDL-cholesterol concentrations.
LIMICOL® contains artichoke extract, red yeast rice, garlic extract, vitamins B2, B3 and E. LIMICOL's effectiveness is based on the synergistic action of eight selected assets along with a well balanced diet and healthy lifestyle.
According to Laboratory LESCUYER®, the company conducted five years of research to submit a complete scientific document that included the results of three proprietary clinical studies to the EFSA.
The company developed a team of medical scientists that worked closely with external contributors to produce the elements for the health claim application. Independent research groups conducted three clinical trials that included a double-blind and placebo-controlled randomized studies on 184 volunteers.
You May Also Like
9 of 10 Amazon galantamine memory supplements failed to meet label claimFeb 23, 2024
ABC reports herbal sales fell 1.9% in 2022Feb 22, 2024
Here's why creatine sales are surging this past yearFeb 21, 2024
DSHEA's 25th anniversary: Industry vets, critics respondFeb 21, 2024